Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say
This article was originally published in The Pink Sheet Daily
ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.
You may also be interested in...
PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.